FI972781L - Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä - Google Patents

Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä Download PDF

Info

Publication number
FI972781L
FI972781L FI972781A FI972781A FI972781L FI 972781 L FI972781 L FI 972781L FI 972781 A FI972781 A FI 972781A FI 972781 A FI972781 A FI 972781A FI 972781 L FI972781 L FI 972781L
Authority
FI
Finland
Prior art keywords
decarboethoxyloratadiene
diseases
compositions
methods
allergic rhinitis
Prior art date
Application number
FI972781A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972781A0 (fi
FI972781A7 (fi
Inventor
A K Gunnar Aberg
John R Mccullough
Emil R Smith
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23443929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI972781(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of FI972781A0 publication Critical patent/FI972781A0/fi
Publication of FI972781A7 publication Critical patent/FI972781A7/fi
Publication of FI972781L publication Critical patent/FI972781L/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI972781A 1994-12-30 1995-12-11 Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä FI972781L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,651 US5595997A (en) 1994-12-30 1994-12-30 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
PCT/US1995/015995 WO1996020708A1 (en) 1994-12-30 1995-12-11 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Publications (3)

Publication Number Publication Date
FI972781A0 FI972781A0 (fi) 1997-06-27
FI972781A7 FI972781A7 (fi) 1997-08-27
FI972781L true FI972781L (fi) 1997-08-27

Family

ID=23443929

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972781A FI972781L (fi) 1994-12-30 1995-12-11 Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä

Country Status (21)

Country Link
US (2) US5595997A (de)
EP (3) EP1078633A3 (de)
JP (1) JP4237822B2 (de)
KR (1) KR100442675B1 (de)
CN (2) CN1935141B (de)
AT (1) ATE339956T1 (de)
AU (1) AU707541B2 (de)
BR (1) BR9510129A (de)
CA (1) CA2208836C (de)
CZ (1) CZ293068B6 (de)
DE (2) DE69535234T2 (de)
DK (1) DK0799037T3 (de)
ES (1) ES2144980T3 (de)
FI (1) FI972781L (de)
HU (1) HU229871B1 (de)
MX (1) MX9704793A (de)
NO (3) NO317555B1 (de)
NZ (1) NZ300398A (de)
PT (1) PT799037E (de)
SK (3) SK287257B6 (de)
WO (1) WO1996020708A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071570C (zh) * 1993-06-14 2001-09-26 詹森药业有限公司 阿司咪唑和假麻黄碱的缓释薄膜包衣片
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
NZ331160A (en) * 1996-02-08 2000-07-28 Merck & Co Inc use of loratadine and a leukotriene antagonist to treat asthma
EP0941091A1 (de) * 1996-10-31 1999-09-15 Schering Corporation Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma
US6308328B1 (en) 1997-01-17 2001-10-23 Scientific-Atlanta, Inc. Usage statistics collection for a cable data delivery system
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
NZ520907A (en) * 1997-12-23 2004-05-28 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
PT968715E (pt) * 1998-06-30 2004-12-31 Pfizer Prod Inc Loratadina para utilizacao como agente anti-arritmico
JP3224379B1 (ja) * 1998-07-10 2001-10-29 シェーリング コーポレイション 8−クロロ−6,11−ジヒドロ−11−(4−ピペリジリデン)−5H−ベンゾ[5,6]シクロヘプタ[1,2−b]ピリジンの経口用組成物
AU6018899A (en) * 1998-09-10 2000-04-03 Schering Corporation Antihistamines for treating non-infective sinusitis or otitis media
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
EP1214072A2 (de) * 1999-09-21 2002-06-19 Schering Corporation Verwendung von desloratadine zur behandlung von entzündlicher und allergischer zustände
CA2383214A1 (en) * 1999-09-22 2001-03-29 Schering Corporation Treating allergic and inflammatory conditions
ES2284531T3 (es) * 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
CA2393837A1 (en) * 1999-12-21 2001-06-28 Schering Corporation Use of desloratadine for treating allergic and inflammatory conditions in pediatric patients
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
WO2001056571A1 (en) * 2000-02-03 2001-08-09 Schering Corporation Treating allergic and inflammatory conditions
WO2001076600A2 (en) * 2000-04-07 2001-10-18 Schering Corporation Inhibition of cytokine generation
WO2002067938A2 (en) * 2000-10-30 2002-09-06 Schering Corporation Treating or reducing the risk of cardiovascular disease
WO2002036124A2 (en) * 2000-10-30 2002-05-10 Schering Corporation Treatment and method using loratadine and montelukast
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
EP1437130A4 (de) * 2001-10-17 2009-08-26 Hisamitsu Pharmaceutical Co Perkutane absorptionszubereitungen
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
ES2258175T3 (es) * 2001-12-05 2006-08-16 Alcon, Inc. Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis.
US20030004179A1 (en) * 2002-05-21 2003-01-02 Affrime Melton B Treating allergic and inflammatory conditions
BR0313231A (pt) * 2002-08-05 2007-07-24 Sandoz Ag sal e polimorfos de hemifumarato de desloratadina
CA2499125C (en) * 2002-09-24 2010-12-14 Morepen Laboratories Limited An improved process for the production of desloratadine
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
CZ200798A3 (cs) * 2004-07-07 2007-06-20 Egis Gyogyszergyár Nyrt. Nový pseudopolymorf desloratadinu vytvorený s oxidem uhlicitým
AU2005263958B2 (en) * 2004-07-16 2011-04-14 Cipla Limited Anti-histaminic composition
US20060154948A1 (en) * 2005-01-12 2006-07-13 Schering Corporation Treating allergic and inflammatory conditions
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
CN104161736A (zh) 2006-06-01 2014-11-26 Msd消费保健品公司 包含去氧肾上腺素的缓释药物制剂
EP2120945A1 (de) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamin-kombination
US20090054338A1 (en) * 2007-08-06 2009-02-26 Aberg A K Gunnar Synergisms between repartitioning and immunomodulating compounds
AU2008302190A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8073633B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
EP2443134A2 (de) 2009-06-16 2012-04-25 Schering Corporation Neue [3,2-c]heteroarylsteroide als glucocorticoidrezeptoragonisten, zusammensetzungen und verwendung
EP2269586B1 (de) 2009-07-01 2011-09-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische Zusammensetzung mit Desloratadin
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) * 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション 8↓−クロル↓−6,11↓−ジヒドロ↓−11↓−(4↓−ピペリジリデン)↓−5H↓−ベンゾ〔5,6〕シクロヘプタ〔1,2−b〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen

Also Published As

Publication number Publication date
HUT77315A (hu) 1998-03-30
CN1935141A (zh) 2007-03-28
CZ293068B6 (cs) 2004-02-18
CN1935141B (zh) 2013-04-24
MX9704793A (es) 1997-10-31
FI972781A0 (fi) 1997-06-27
HK1008185A1 (en) 1999-05-07
CN1176598A (zh) 1998-03-18
SK88897A3 (en) 1998-02-04
US5595997A (en) 1997-01-21
DE799037T1 (de) 2000-10-05
CN1267098C (zh) 2006-08-02
US5731319A (en) 1998-03-24
DK0799037T3 (da) 2007-02-12
EP0799037A1 (de) 1997-10-08
JPH10512240A (ja) 1998-11-24
EP1078633A3 (de) 2001-03-07
EP1078633A2 (de) 2001-02-28
SK284834B6 (sk) 2005-12-01
AU707541B2 (en) 1999-07-15
CA2208836A1 (en) 1996-07-11
NO20020211L (no) 1997-08-19
NO20020211D0 (no) 2002-01-15
CA2208836C (en) 2001-12-04
AU4512696A (en) 1996-07-24
NZ300398A (en) 2001-04-27
EP0799037B1 (de) 2006-09-20
BR9510129A (pt) 1997-12-30
ATE339956T1 (de) 2006-10-15
NO973023L (no) 1997-08-19
SK286079B6 (sk) 2008-03-05
FI972781A7 (fi) 1997-08-27
EP0799037A4 (de) 1998-05-06
NO973023D0 (no) 1997-06-27
DE69535234T2 (de) 2007-09-13
CZ202697A3 (cs) 1998-03-18
DE69535234D1 (de) 2006-11-02
NO317555B1 (no) 2004-11-15
SK287257B6 (sk) 2010-05-07
EP1712232A1 (de) 2006-10-18
ES2144980T3 (es) 2007-03-16
JP4237822B2 (ja) 2009-03-11
KR100442675B1 (ko) 2004-10-14
WO1996020708A1 (en) 1996-07-11
PT799037E (pt) 2006-12-29
NO20110077L (no) 1997-08-19
ES2144980T1 (es) 2000-07-01
HU229871B1 (en) 2014-11-28
NO330421B1 (no) 2011-04-11

Similar Documents

Publication Publication Date Title
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI970771L (fi) Uusia allergisten sairauksien hoidossa käyttökelpoisia substituoituja piperidiinejä
FI971171A7 (fi) Koostumukset ja menetelmät syöttösolujen välittämien tulehdussairauksi en hoitamiseksi
FI963696A7 (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
KR950700732A (ko) 알러지성 및 염증성 질환의 치료에 유용한 화합물(Compounds useful for treating allergic and inflammatory diseases)
FI940932A7 (fi) Koostumuksia ja menetelmiä haavojen hoitamiseksi
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
NO972972L (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
ATE148632T1 (de) Synergistische therapeutische zusammensetzungen und verfahren
FI964162L (fi) Aineyhdistelmä ja menetelmä kasvisairauksien säätämiseksi
FI971349L (fi) Asfaltin irrote ja käyttömenetelmä
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
FI971750A0 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI970534L (fi) Menetelmät ja koostumukset endotoksiinin liittyvien tilojen ennaltaehkäisemiseksi ja hoitamiseksi
FI951060A7 (fi) Formulaatioita ja hoitomenetelmiä
FI972235A0 (fi) Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin hoidossa ja ehkäisyssä
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
FI965008L (fi) Koostumukset ja menetelmät kasvainten hoitamiseksi
FI954245A0 (fi) Koostumuksia ja menetelmiä immunovälitteisten tulehduksellisten häiriöiden hoitamiseksi
FI963325A7 (fi) Inhibiinikoostumukset ja menetelmät niiden käyttämiseksi
FI971584A7 (fi) Estävä ja hoitava aine tyypin I allergiatauteja varten
FI972929A0 (fi) Kollageeniin perustuvia menetelmiä ja koostumuksia immuunijärjestelmän välittämien sairauksien hoitamiseksi
FI972530L (fi) Menetelmä substituoitujen 4-etyyli-piperidiinien valmistamiseksi ja niiden valmistuksessa käytettävä välituote
FI911268A7 (fi) Menetelmä ja koostumus iontoforeesia varten

Legal Events

Date Code Title Description
FC Application refused
RF Appeal filed